HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
Huagongshe Open Program：[email protected]AI access: llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.7.8
Back
HuagongsheHuagongshe Chemistry Print Report · For research reference only
HCID 3950Generated: October 27, 2026

Lomustine

Lomustin · cinu · CCNU · ceenu · rb1509 · cecenu · sri2200 · nsc79037

https://huagongshe.com/en/chemical/3950

Lomustine molecular structure

Identifiers & Physical Properties

CAS No.13010-47-4
Molecular formulaC9H16ClN3O2
Average molar mass233.69 g/mol
Monoisotopic mass233.0931045 g/mol
SMILESO=NN(CCCl)C(=O)NC1CCCCC1
InChIKeyGQYIWUVLTXOXAJ-UHFFFAOYSA-N
PubChem CID3950
ChEMBLCHEMBL2062293
ChEBICHEBI:6520
EC No.235-859-2
DTXSIDDTXSID2023222

Chemical & Physical Properties

XLogP2.8
Topological polar surface area61.8
Hydrogen bond donors1
Hydrogen bond acceptors3
Rotatable bonds3
Heavy atoms15
Formal charge0
Complexity219
DrugsPharmaceuticals -> Listed in ZINC15
SpringerMaterials Properties15N nuclear magnetic resonance spectrum
LogP (partition coefficient)log Kow = 2.83
Color/FormSolidYellow powder
SolubilitySoluble in ethanolFreely soluble in chloroformsoluble in acetone.Solubility in water, 0.1N NaOH, 0.1N HCl, or 10% ethanol: <0.05 mg/mLin absolute ethanol: 70 mg/mL7.55e-01 g/LPractically insoluble in water, freely soluble in acetone and in methylene chloride, soluble in ethanol (96 per cent).
Human DrugsFDA approved drugs -> Active ingredient
DecompositionHazardous decomposition products formed under fire conditions: Carbon oxides, nitrogen oxides (NOx), hydrogen chloride gas.
Melting point88-90 °C88 - 90 °C
Physical DescriptionSolid
Boiling point63.6°C (rough estimate)
Density1.3840 (rough estimate)
Refractive index1.5790 (estimate)
Storage conditions2-8°C
pKa (acidity coefficient)10.88±0.20(Predicted)
Physical stateSolid
ColorLight orange to Yellow to Green
Merck14,5564
Henry's law constant5.5×104 mol/(m3Pa) at 25℃, HSDB (2015)
InChIInChI=1S/C9H16ClN3O2/c10-6-7-13(12-15)9(14)11-8-4-2-1-3-5-8/h8H,1-7H2,(H,11,14)
InChIKeyGQYIWUVLTXOXAJ-UHFFFAOYSA-N
SMILESN(CCCl)(N=O)C(NC1CCCCC1)=O
CAS DataBase Reference13010-47-4(CAS DataBase Reference)
NCI Dictionary of Cancer TermsCCNUlomustine
FDA UNII7BRF0Z81KG
NCI Drug Dictionarylomustine
ATC codeL01AD02
IARC2A (Vol. 26, Sup 7) 1987
EPA Substance Registry System1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (13010-47-4)
UNSPSC Code41116107
NACRESNA.25
Protein binding60%
Excreted unchanged in urine50 (as metabolites)
Biological half-life16-48 (metabolites)
GHS pictogramGHS06,GHS08
Signal wordDanger
GHS hazard statementsH301-H350
GHS precautionary statementsP201-P280-P301+P330+P331+P310-P308+P313
Personal protective equipment (PPE)Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges
Hazard symbolsT
Risk statements (R)45-25
Safety statements (S)53-45
UN transport number3249
Water hazard class (WGK)3
RTECS numberYS4900000
Hazard class6.1(a)Acute Tox. 3 OralCarc. 1B
Packing groupII
Customs code29299090
Storage class6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
Hazardous substances data13010-47-4(Hazardous Substances Data)
ToxicityLD50 in male mice (mg/kg): 51 orally56 i.p.61 s.c. (Thompson, Larson)

Safety & Regulations

GHS classificationDangerH228 (34.4%): Flammable solid [Danger Flammable solids]P203, P210, P234, P235, P240, P241, P260, P264, P270, P280, P301+P316, P308+P316, P318, P319, P321, P330, P370+P378, P403, P405, P410, P411, P420, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 64 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.H301: Toxic if swallowed [Danger Acute toxicity, oral]
Regulatory informationHazard Traits - CarcinogenicityDevelopmental Toxicity
Other safety informationIMAP assessments - Urea, N-(2-chloroethyl)-N'-cyclohexyl-N-nitroso-: Environment tier I assessment
FDA requirementsThe Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl lomustine, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.
Special ReportsNational Toxicology Program. Eleventh Report on Carcinogens (2005). The Report on Carcinogens is an informational scientific and public health document that identifies and discusses substances (including agents, mixtures, or exposure circumstances) that may pose a carcinogenic hazard to human health. 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (13010-47-4) is listed as reasonably anticipated to be a human carcinogen. First listed in the Fourth Annual Report on Carcinogens (1985) as reasonably anticipated to be a human carcinogen.[Available from, as of July 31, 2009: http://ntp.niehs.nih.gov/ntp/roc/eleventh/profiles/s035ccnu.pdf]
Toxic Combustion ProductsHazardous decomposition products formed under fire conditions: Carbon oxides, nitrogen oxides (NOx), hydrogen chloride gas.
Hazard Classes and CategoriesFlam. Sol. 1 (34.4%)Acute toxicity (Oral) - Category 3
Shipment Methods and Regulations/PRECAUTIONS FOR ANTINEOPLASTIC AGENTS:/ Methods for transporting hazardous drugs to the health-care setting should be consistent with environmental protection and national or local regulations for transporting hazardous substances. When hazardous drugs are being transported to the home-care setting, appropriate containers (eg, lined cardboard boxes) and procedures should be used to prevent breakage and contain leakage. ... The drugs must be securely capped or sealed and properly packaged and protected during transport to reduce further the chance of breakage and spillage in a public area such as a corridor or elevator. /Antineoplastic agents/

Applications & Uses

Description

Lomustine is a pale yellow powder. Molecularweight = 233.73; Freezing/Melting point = 90℃. Insolublein water.

Uses

Chloroethylnitrosourea derivative with antitumor activity. Similar to carmustine, chlorozotocin, nimustine, ranimustine. Antineoplastic.

Uses

CCNU is an oral anticancer drug that was approved by the U.S. Food and Drug Administration in 1976 for marketing, as lomustine (FDA 2009a). CCNU is used alone or in combination with other antineoplastic agents, including procarbazine and vincristine, etoposide and prednimustine, and other combinations (IARC 1981, HSDB 2009). It is used primarily in the treatment of Hodgkin’s disease and brain tumors, but it has also been used to treat other cancer, includ-ing lung cancer, non-Hodgkin’s lymphoma, malignant melanoma, breast cancer, kidney cancer, and cancer of the gastrointestinal tract (MedlinePlus 2009). It has also been applied to the skin to treat mycosis fungoides and psoriasis.

Uses

Lomustine USP is used to treat Malignant brain tumors; Hodgkin’s disease.

General Description

Lomustine is available in 10-, 40-, and 100-mg capsules fororal administration in the treatment of primary and metastaticbrain cancers and Hodgkin’s lymphoma. This lipophilicagent is well absorbed, widely distributed, and crosses theblood-brain barrier. Lomustine undergoes extensive hepaticmetabolism, which is mediated by CYP3A4 to give severalhydroxylated metabolites, which arise as a result of oxidationof the cyclohexyl ring. Several of these are more activethan the parent compound. Denitrosation and dechlorinationhave also been demonstrated to occur for lomustine as well.The intact drug was not found in plasma when the agent wasadministered orally. Elimination occurs primarily in theurine with an elimination half-life of 16 to 72 hours.Myelosuppression is dose limiting and presents in a mannersimilar to that seen with carmustine. Other toxicities includenausea, vomiting, anorexia, impotence, sterility, amenorrhea,and infertility. Pulmonary and renal toxicity are rarelyseen during standard-dose therapy but increase during highdosetherapy.

PRECAUTIONS FOR "CARCINOGENS": Procurement ... of unduly large amt ... should be avoided. To avoid spilling, carcinogens should be transported in securely sealed glass bottles or ampoules, which should themselves be placed inside strong screw-cap or snap-top container that will not open when dropped & will resist attack from the carcinogen. Both bottle & the outside container should be appropriately labelled. ... National post offices, railway companies, road haulage companies & airlines have regulations governing transport of hazardous materials. These authorities should be consulted before ... material is shipped. /Chemical Carcinogens/
PRECAUTIONS FOR "CARCINOGENS": When no regulations exist, the following procedure must be adopted. The carcinogen should be enclosed in a securely sealed, watertight container (primary container), which should be enclosed in a second, unbreakable, leakproof container that will withstand chem attack from the carcinogen (secondary container). The space between primary & secondary container should be filled with absorbent material, which would withstand chem attack from the carcinogen & is sufficient to absorb the entire contents of the primary container in the event of breakage or leakage. Each secondary container should then be enclosed in a strong outer box. The space between the secondary container & the outer box should be filled with an appropriate quantity of shock-absorbent material. Sender should use fastest & most secure form of transport & notify recipient of its departure. If parcel is not received when expected, carrier should be informed so that immediate effort can be made to find it. Traffic schedules should be consulted to avoid ... arrival on weekend or holiday ... /Chemical Carcinogens/
Shipping Name/ Number DOT/UN/NA/IMOUN2811, Toxic solid, organic, NOS (Lomustine)[Sigma-AldrichSafety Data Sheet for Lomustine (Product Number: L5918) Version 3.1 (June 19, 2009). Available from, as of November 20, 2009: http://www.sigmaaldrich.com]
Skin, Eye, and Respiratory Irritations... May cause respiratory tract irritation. ... May cause skin irritation. May cause eye irritation.
Hazardous Reactivities and IncompatibilitiesMaterials to avoid: Strong oxidizing agents, strong bases.
Fire fighting proceduresSuitable extinguishing media: Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.Special protective equipment for fire-fighters: Wear self contained breathing apparatus for fire fighting if necessary.
Storage conditionsStore in cool place. Keep container tightly closed in a dry and well-ventilated place. Recommended storage temperature: -20 °C. Light sensitive.Commercially available lomustine capsules should be stored in well-closed containers at a temperature less than 40 °C.The bulk drug should be stored in a deep freeze and protected from moisture.PRECAUTIONS FOR "CARCINOGENS": Storage site should be as close as practical to lab in which carcinogens are to be used, so that only small quantities required for ... expt need to be carried. Carcinogens should be kept in only one section of cupboard, an explosion-proof refrigerator or freezer (depending on chemicophysical properties ...) that bears appropriate label. An inventory ... should be kept, showing quantity of carcinogen & date it was acquired ... Facilities for dispensing ... should be contiguous to storage area. /Chemical Carcinogens/
Cleanup methodsPersonal precautions: Use personal protective equipment. Avoid dust formation. Avoid breathing dust. Ensure adequate ventilation. Evacuate personnel to safe areas.Environmental precautions: Prevent further leakage or spillage if safe to do so. Do not let product enter drains.Methods for cleaning up: Pick up and arrange disposal without creating dust. Keep in suitable, closed containers for disposal./PRECAUTIONS FOR ANTINEOPLASTIC AGENTS:/ Spill kits containing all materials needed to clean up spills of hazardous drugs should be assembled or purchased. These kits should be readily available in all areas where hazardous drugs are routinely handled. If hazardous drugs are being prepared or administered in a nonroutine area (home setting or unusual patient-care area), a spill kit should be obtained by the drug handler. The kit should include two pairs of disposable gloves (one outer pair of utility gloves and one inner latex pair)low-permeability, disposable protective garments (coveralls or gown and shoe covers)safety glasses or splash gogglesrespiratorabsorbent, plastic-backed sheets or spill padsdisposable towelingat least 2 sealable thick plastic hazardous waste disposal bags (prelabeled with an appropriate warning label)a disposable scoop for collecting glass fragmentsand a puncture-resistant container for glass fragments. All individuals who routinely handle hazardous drugs must be trained in proper spill management and cleanup procedures. Spills and breakages must be cleaned up immediately according to the following procedures. If the spill is not located in a confined space, the spill area should be identified and other people should be prevented from approaching and spreading the contamination. Wearing protective apparel from the spill kit, workers should remove any broken glass fragments and place them in the puncture-resistant container. Liquids should be absorbed with a spill padpowder should be removed with damp disposable gauze pads or soft toweling. The hazardous material should be completely removed and the area rinsed with water and then cleaned with detergent. The spill cleanup should proceed progressively from areas of lesser to greater contamination. The detergent should be thoroughly rinsed and removed. All contaminated materials should be placed in the disposal bags provided and sealed and transported to a designated containment receptacle. Spills occurring in the biohazard cabinet should be cleaned up immediatelya spill kit should be used if the volume exceeds 150 ml or the contents of one drug vial or ampule. If there is broken glass, utility gloves should be worn to remove it and place it in the puncture-resistant container located in the biohazard cabinet. The biological safety cabinet, including the drain spillage trough, should be thoroughly cleaned. If the spill is not easily and thoroughly contained, the biological safety cabinet should be decontaminated after cleanup. If the spill contaminates the high efficiency particulate air filter, use of the biological safety cabinet should be suspended until the cabinet has been decontaminated and the high efficiency particulate air filter replaced. /Antineoplastic agents/For more Cleanup Methods (Complete) data for LOMUSTINE (6 total), please visit the HSDB record page.
Disposal methodsSRP: Criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.Dissolve or mix the material with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber. Observe all federal, state, and local environmental regulations. Contact a licensed professional waste disposal service to dispose of this material./PRECAUTIONS FOR ANTINEOPLASTIC AGENTS:/ All contaminated disposables should be contained in sealable bags for transfer to larger waste containers. /Antineoplastic agents//PRECAUTIONS FOR ANTINEOPLASTIC AGENTS:/ All bottles must be discarded as contaminated waste after decontamination of the biohazard cabinet. All protective apparel (gown, gloves, goggles, and respirator) should be discarded as contaminated waste. /Antineoplastic agents/For more Disposal Methods (Complete) data for LOMUSTINE (14 total), please visit the HSDB record page.
Preventive MeasuresIn case of skin contact: Wash off with soap and plenty of water. Consult a physician.In case of eye contact: Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.Hygiene measures: Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling the product./PRECAUTIONS FOR ANTINEOPLASTIC AGENTS:/ Accidental contamination of the health-care environment, resulting in exposure of personnel, patients, visitors, and family members to hazardous substances, is prevented by maintaining the physical integrity and security of packages of hazardous drugs. 1. Access to all areas where hazardous drugs are stored is limited to specified authorized staff. 2. A method should be present for identifying to personnel those drugs that require special precautions (eg, cytotoxics). One way to accomplish this is to apply appropriate warning labels to all hazardous drug containers, shelves, and bins where the drug products are stored. ... 3. A method of identifying, for patients and family members, those drugs that require special precautions in the home should be in place. This may be accomplished in the health-care setting, by providing specific labeling for discharge medications, along with written instructions. 4. Methods for identifying shipping cartons of hazardous drugs should be required from manufacturers and distributors of these drugs. 5. Written procedures for handling damaged packages of hazardous drugs should be maintained. Personnel involved in shipping and receiving hazardous drugs should be trained in these procedures, including the proper use of protective garments and equipment. Damaged shipping cartons of hazardous drugs should be received and opened in an isolated area (eg, in a laboratory fume hood, if available, not in a vertical laminar airflow biological safety cabinet used for preparing sterile products). /Antineoplastic agents/For more Preventive Measures (Complete) data for LOMUSTINE (32 total), please visit the HSDB record page.
Personal Protective Equipment (PPE)Respiratory protection: Where risk assessment shows air-purifying respirators are appropriate use a full-face particle respirator type N99 (US) or type P2 (EN 143) respirator cartridges as a backup to engineering controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).Hand protection: The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and the standard EN 374 derived from it. Handle with gloves.Eye protection: Face shield and safety glasses.Skin and body protection: Choose body protection according to the amount and concentration of the dangerous substance at the work place.For more Personal Protective Equipment (PPE) (Complete) data for LOMUSTINE (10 total), please visit the HSDB record page.
InteractionsThe combined action of the antitumor antibiotic bleomycin and chloroethylnitrosourea was studied in human lymphocytes in vitro. All the experiments were carried out with 20 ug/mL bleomycin for a given treatment time. By adding 0.7 and 3.5 ug/mL chloroethylnitrosourea at late G1-S phase we have demonstrated a considerable increase in both percent of aberrant cells and production of dicentrics and rings (5-fold, p < 0.001). At late S-G2 the combined treatment led to a significant enhancement of breaks per cell (p < 0.0001) and cells with more than 12 aberrations. A possible explanation could be the known repair inhibitory potential of chloroethylnitrosourea, but its pure clastogenic action still has to be considered. The results presented here point out the need for seeking chemotherapeutic regimens with reduced concentrations of the drugs in combination.Three patients developed the sudden onset of total blindness several months after treatment with oral CCNU and low dose whole brain radiation. The anterior visual system was included in the radiation field in all patients. Radiotherapy was given for a frontal lobe glioblastoma multiforme, for central nervous system prophylaxis in a patient with oat cell carcinoma of the lung, and for a parietal lobe glioblastoma multiforme. None of the neoplasms involved the anterior visual system. The radiation dose ranged from 3000 to 4650 rad and the oral CCNU dosage from 300 mg to 1050 mg. Patients 1 and 2 also received other chemotherapeutic agents. Patient 3 who was treated only with oral CCNU and cranial irradiation died. At autopsy the brain showed a widely infiltrating residual high grade glioma as well as patchy coagulative necrosis with swollen axons and dystrophic calcifications. The optic chiasm showed severe demyelination, axonal loss, and hyalinized vessels. Synergism between oral CCNU and radiation may account for the blindness produced.
HepatotoxicityMild and transient elevations in serum aminotransferase or alkaline phosphatase levels are found in a high proportion of patients treated antineoplastic regimens that include lomustine. The abnormalities are generally transient, do not cause symptoms and do not require dose modification. Clinically apparent liver injury from lomustine has been described, but is uncommon. The pattern of serum enzyme elevations were described as cholestatic and onset was after 3 to 4 months of therapy, but otherwise its clinical characteristics have not been clearly characterized. Lomustine is often given in combination with other antineoplastic agents, many of which are also hepatotoxic, so the effect of lomustine in causing liver injury is often difficult to assess. Lomustine has not been associated specifically with sinusoidal obstruction syndrome, but it is not generally given in high doses or used for myeloablation in preparation for bone marrow transplantation, the situations in which this syndrome generally occurs.
Environmental fateTERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 200(SRC), determined from a structure estimation method(2), indicates that lomustine is expected to have moderate mobility in soil(SRC). However, by analogy to N-nitroso-N-ethylurea which exhibited a hydrolysis half-life of 47 minutes at pH 9(3), adsorption may be precluded by hydrolysis(SRC). Volatilization of lomustine from moist soil surfaces is not expected to be an important fate process(SRC) given an estimated Henry's Law constant of 1.8X10-10 atm-cu m/mole(SRC), using a fragment constant estimation method(4). Lomustine is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 2.6X10-5 mm Hg(SRC), determined from a fragment constant method(5). Biodegradation data were not available(SRC, 2009).AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 200(SRC), determined from a structure estimation method(2), indicates that lomustine is expected to adsorb to suspended solids and sediment(SRC). However, by analogy to N-nitroso-N-ethylurea which exhibited a hydrolysis half-life of 47 minutes at pH 9(3), adsorption may be precluded by hydrolysis(SRC). Volatilization from water surfaces is not expected(4) based upon an estimated Henry's Law constant of 1.8X10-10 atm-cu m/mole(SRC), developed using a fragment constant estimation method(5). According to a classification scheme(6), an estimated BCF of 34(SRC), from its log Kow of 2.83(7) and a regression-derived equation(8), suggests the potential for bioconcentration in aquatic organisms is moderate(SRC). Lomustine is an alkylating agent that may hydrolyze under environmental conditions(4). Biodegradation data were not available(SRC, 2009).ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), lomustine, which has an estimated vapor pressure of 2.6X10-5 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), will exist in both the vapor and particulate phases in the ambient atmosphere. Vapor-phase lomustine is degraded in the atmosphere by reaction with photochemically-produced hydroxyl radicals(SRC)the half-life for this reaction in air is estimated to be 18 hours(SRC), calculated from its rate constant of 2.2X10-11 cu cm/molecule-sec at 25 °C(SRC) that was derived using a structure estimation method(3). Particulate-phase lomustine may be removed from the air by wet or dry deposition(SRC). Lomustine does not contain chromophores that absorb at wavelengths >290 nm(4) and therefore is not expected to be susceptible to direct photolysis by sunlight(SRC).
Exposure routesWell and rapidly absorbed from the gastrointestinal tract.
Milk ConcentrationsLomustine metabolites are present in milk, but in concentrations than those in maternal plasma.
Toxicity summaryLomustine is a highly lipophilic nitrosourea compound which undergoes hydrolysis in vivo to form reactive metabolites. These metabolites cause alkylation and cross-linking of DNA (at the O6 position of guanine-containing bases) and RNA, thus inducing cytotoxicity. Other biologic effects include inhibition of DNA synthesis and some cell cycle phase specificity. Nitrosureas generally lack cross-resistance with other alkylating agents. As lomustine is a nitrosurea, it may also inhibit several key processes such as carbamoylation and modification of cellular proteins.
Ongoing Test StatusThe following link will take the user to the National Toxicology Program (NTP) Test Agent Search Results page, which tabulates all of the "Standard Toxicology & Carcinogenesis Studies", "Developmental Studies", and "Genetic Toxicity Studies" performed with this chemical. Clicking on the "Testing Status" link will take the user to the status (i.e., in review, in progress, in preparation, on test, completed, etc.) and results of all the studies that the NTP has done on this chemical.[Available from: http://ntp-apps.niehs.nih.gov/ntp_tox/index.cfm?fuseaction=ntpsearch.searchresults&searchterm=13010-47-4]
Medical Surveillance/PRECAUTIONS FOR ANTINEOPLASTIC AGENTS:/ There is no method available for routine monitoring of personnel for evidence of hazardous drug exposure. Tests for the presence of mutagens or chromosomal damage are not drug specific and are of value only in controlled studies. Chemical analysis of urine for the presence of hazardous drugs at the sensitivity level needed to detect occupational exposure is limited to a few drugs and is not yet commercially available. /Antineoplastic agents/PRECAUTIONS FOR "CARCINOGENS": Whenever medical surveillance is indicated, in particular when exposure to a carcinogen has occurred, ad hoc decisions should be taken concerning ... /cytogenetic and/or other/ tests that might become useful or mandatory. /Chemical Carcinogens/
Soil Adsorption/MobilityUsing a structure estimation method based on molecular connectivity indices(1), the Koc of lomustine can be estimated to be 200(SRC). According to a classification scheme(2), this estimated Koc value suggests that lomustine is expected to have moderate mobility in soil. However, by analogy to N-nitroso-N-ethylurea which exhibited a hydrolysis half-life of 47 minutes at pH 9(3), adsorption may be precluded by hydrolysis(SRC).
Human Toxicity Excerpts/SIGNS AND SYMPTOMS/ The occurrence of acute leukemia and bone marrow dysplasias have been reported in patients following long-term nitrosourea therapy./SIGNS AND SYMPTOMS/ Pulmonary toxicity, sometimes fatal, has occurred rarely in patients receiving lomustine. Pulmonary toxicity characterized by pulmonary infiltrates and/or fibrosis has occurred at 6 months or longer following initiation of lomustine therapy in patients typically receiving cumulative doses exceeding 1100 mg/sq mhowever, pulmonary fibrosis has occurred with lower total doses./SIGNS AND SYMPTOMS/ Delayed onset of pulmonary fibrosis occurring up to 17 years after treatment has been reported in patients receiving related nitrosoureas combined with cranial radiation therapy for intracranial tumors during childhood and adolescence (age 1-16 years). Late onset of reduction in pulmonary function was observed in all long-term survivors. Nitrosourea-induced pulmonary fibrosis may be slowly progressive and can cause death.For more Human Toxicity Excerpts (Complete) data for LOMUSTINE (11 total), please visit the HSDB record page.
Artificial Pollution SourcesLomustine's production and use as an antineoplastic(1) may result in its release to the environment through various waste streams(SRC).
Carcinogen Classification1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) (Lomustine)Group 2A: Probably carcinogenic to humansVolume 26: (1981) Some Antineoplastic and Immunosuppressive Agents1987NB Overall evaluation upgraded to Group 2A with supporting evidence from other relevant data
Personal protective equipment (PPE)Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges
Water hazard class (WGK)3
RTECS numberYS4900000
UN transport number3249
Customs code29299090
ToxicityLD50 in male mice (mg/kg): 51 orally56 i.p.61 s.c. (Thompson, Larson)
Risk statements (R)45-25
Signal wordDanger
GHS pictogramGHS06,GHS08
Hazard symbolsT
Safety statements (S)53-45
Hazard class6.1(a)Acute Tox. 3 OralCarc. 1B
Storage class6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
Packing groupII
GHS hazard statementsH301-H350
GHS precautionary statementsP201-P280-P301+P330+P331+P310-P308+P313
Hazardous substances data13010-47-4(Hazardous Substances Data)